Pesquisar
Telix Pharmaceuticals Ltd
TLXAdicionar à lista de desejos
11.280USD
-0.670-5.61%
Horário de mercado 09/23, 12:33（ET）
0.00Valor de mercado
0.00P/L TTM
Sobre o Telix Pharmaceuticals Ltd Empresa
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd Perfil
Código da empresaTLX
Nome da EmpresaTelix Pharmaceuticals Ltd
Data de listagemNov 15, 2017
CEOOrtiz (Raphaeel)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
Endereço55 Flemington Road
CidadeMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3051
Telefone61390933855
Sitehttps://telixpharma.com/
Código da empresaTLX
Data de listagemNov 15, 2017
CEOOrtiz (Raphaeel)
Executivos da empresa Telix Pharmaceuticals Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Ms. Marie McDonald
Ms. Marie McDonald
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David Gill
Mr. David Gill
Non-Executive Chair of the Board
Non-Executive Chair of the Board
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Telix Pharmaceuticals Ltd?
Os cinco principais acionistas de Telix Pharmaceuticals Ltd são: Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Quantas instituições possuem ações da Telix Pharmaceuticals Ltd (TLX)?
Em 2026Q1, 61 instituições possuíam ações da Telix Pharmaceuticals Ltd, com valor de mercado aproximado de 1.47M, representando 0.43% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 326197.00.